Ruth Itzhaki, MSc, PhD, MA, University of Manchester, Manchester, UK, discusses the prophylactic potential of antiviral therapy to prevent people infected with herpes simplex virus and carry the apolipoprotein E-ε4 (APOE) gene from developing dementia. Current trials utilize drugs that inhibit DNA replication and Prof. Itzhaki highlights using treatments with alternative mechanisms of action such as anti-inflammatory drugs or ones that prevent viral entry. She additionally suggests conducting a long-term clinical trial assessing the efficacy of prophylactic antiviral therapy in patients with herpes. This interview was conducted during the 2022 World Congress on Controversies in Neurology (CONy) meeting.